Moderna (MRNA) Capital Expenditures (2018 - 2026)

Moderna (MRNA) has 9 years of Capital Expenditures data on file, last reported at $35.0 million in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 70.09% year-over-year to $35.0 million in Q1 2026; TTM through Mar 2026 was $110.0 million, a 511.11% increase from a year earlier, with the FY2025 full-year figure at $192.0 million, up 97.94% from the prior year.
• Capital Expenditures for Q1 2026 stood at $35.0 million, down from $39.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for MRNA reached as high as $559.0 million in Q4 2023 and fell as low as -$300.0 million in Q3 2024.
• Historically, Capital Expenditures has averaged $84.2 million across 5 years, with a median of $89.0 million in 2022.
• Across the five-year window, Capital Expenditures jumped 8800.0% in 2022 and plunged 797.67% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $92.0 million in 2022, then jumped by 507.61% to $559.0 million in 2023, then plunged by 96.6% to $19.0 million in 2024, then soared by 105.26% to $39.0 million in 2025, then declined by 10.26% to $35.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $35.0 million in Q1 2026, $39.0 million in Q4 2025, and $106.0 million in Q3 2025.